CLAVAMOX- amoxicillin and clavulanate potassium tablet, film coated

Clavamox by

Drug Labeling and Warnings

Clavamox by is a Animal medication manufactured, distributed, or labeled by Zoetis Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

SPL UNCLASSIFIED SECTION

CLAVAMOX

(amoxicillin and clavulanate potassium tablets), USP

Veterinary Tablets

For use in dogs and cats

CAUTION

 Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

Clavamox (amoxicillin and clavulanate potassium tablets), USP is an orally administered formulation comprised of the broadspectrum antibiotic Amoxi® (amoxicillin trihydrate) and the β- lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid).

Amoxicillin trihydrate is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative, aerobic and anaerobic microorganisms. It does not resist destruction by β-lactamases; therefore, it is not effective against β-lactamase-producing bacteria. Chemically, it is D(-)-α-amino-p-hydroxybenzyl penicillin trihydrate.

Clavulanic acid, an inhibitor of β-lactamase enzymes, is produced by the fermentation of Streptomyces clavuligerus . Clavulanic acid by itself has only weak antibacterial activity. Chemically, clavulanate potassium is potassium z-(3R,5R)-2-β-hydroxyethylidene clavam-3-carboxylate.

ACTIONS

Clavamox is stable in the presence of gastric acid and is not significantly influenced by gastric or intestinal contents. The 2 components are rapidly absorbed resulting in amoxicillin and clavulanic acid concentrations in serum, urine, and tissues similar to those produced when each is administered alone.

Amoxicillin and clavulanic acid diffuse readily into most body tissues and fluids with the exception of brain and spinal fluid, which amoxicillin penetrates adequately when meninges are inflamed. Most of the amoxicillin is excreted unchanged in the urine. Clavulanic acid's penetration into spinal fluid is unknown at this time. Approximately 15% of the administered dose of clavulanic acid is excreted in the urine within the first 6 hours.

Clavamox combines the distinctive properties of a broad-spectrum antibiotic and a β-lactamase inhibitor to effectively extend the antibacterial spectrum of amoxicillin to include β-lactamase producing as well as non-β-lactamase-producing aerobic and anaerobic organisms.

MICROBIOLOGY

Amoxicillin is bactericidal in action and acts through the inhibition of biosynthesis of cell wall mucopeptide of susceptible organisms. The action of clavulanic acid extends the antimicrobial spectrum of amoxicillin to include organisms resistant to amoxicillin and other β-lactam antibiotics. Amoxicillin/ clavulanate has been shown to have a wide range of activity which includes β-lactamaseproducing strains of both gram positive and gram-negative aerobes, facultative anaerobes, and obligate anaerobes. Many strains of the following organisms, including β-lactamase-producing strains, isolated from veterinary sources, were found to be susceptible to amoxicillin/ clavulanate in vitro but the clinical significance of this activity has not been demonstrated for some of these organisms in animals.

Aerobic bacteria, including Staphylococcus aureus*, β-lactamase- producing Staphylococcus aureus* (penicillin resistant), Staphylococcus species*, Staphylococcus epidermidis, Staphylococcus intermedius, Streptococcus faecalis, Streptococcus species*, Corynebacterium pyogenes, Corynebacterium species, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Escherichia coli *, Proteus mirabilis, Proteus species, Enterobacter species, Klebsiella pneumoniae, Salmonella dublin, Salmonella typhimurium,Pasteurella multocida, Pasteurella haemolytica, Pasteurella species*.

* The susceptibility of these organisms has also been demonstrated in in vivo studies.

Studies have demonstrated that both aerobic and anaerobic flora are isolated from gingival cultures of dogs with clinical evidence of peridontal disease. Both gram-positive and gram-negative aerobic and anaerobic subgingival isolates indicate sensitivity to amoxicillin/ clavulanic acid during antimicrobial susceptibility testing.

SUSCEPTIBILITY TEST

The recommended quantitative disc susceptibility method (FEDERAL REGISTER 37:20527–29; Bauer AW, Kirby WMM, Sherris JC, et al: Antibiotic susceptibility testing by standardized single disc method. Am J Clin Path 45:493, 1966) utilized 30 mcg Augmentin® (AMC) discs for estimating the susceptibility of bacteria to Clavamox Tablets.

INDICATIONS

Clavamox Tablets are indicated in the treatment of:

Dogs

 Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli.

Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease

Cats

Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Therapy may be initiated with Clavamox prior to obtaining results from bacteriological and susceptibility studies. A culture should be obtained prior to treatment to determine susceptibility of the organisms to Clavamox. Following determination of susceptibility results and clinical response to medication, therapy may be reevaluated.

CONTRAINDICATIONS

The use of this drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins.

WARNINGS

Safety of use in pregnant or breeding animals has not been determined. Store in a dry, cool place at temperatures not above 25°C (77°F).

Do not remove from foil strip until ready to use.

ADVERSE REACTIONS

Clavamox contains a semisynthetic penicillin (amoxicillin) and has the potential for producing allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids.

Post-Approval Experience (July, 2017)

The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data.

The following adverse events reported for dogs and cats are listed in decreasing order of reporting frequency for CLAVAMOX: Anorexia, lethargy, vomiting and diarrhea.

To report suspected adverse reactions, to obtain a Safety Data Sheet, or for technical assistance, call 1-888-963-8471.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/AnimalVeterinary/SafetyHealth.

DOSAGE AND ADMINISTRATION:

Dogs

The recommended dosage is 6.25 mg/lb of body weight twice a day.

Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5–7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Cats

The recommended dosage is 62.5 mg twice a day.

Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5–7 days or for 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated.

Urinary tract infections may require treatment for 10–14 days or longer. The maximum duration of treatment should not exceed 30 days.

HOW SUPPLIED

Clavamox Tablets in the following strengths are supplied in strip packs. Each carton holds 15 strips with 14 tablets per strip (210 tablets per carton).

Each 62.5-mg tablet contains amoxicillin trihydrate equivalent to 50 mg of amoxicillin activity and 12.5 mg of clavulanic acid as the potassium salt. For use in dogs and cats.

Each 125-mg tablet contains amoxicillin trihydrate equivalent to 100 mg of amoxicillin activity and 25 mg of clavulanic acid as the potassium salt. For use in dogs only.

Each 250-mg tablet contains amoxicillin trihydrate equivalent to 200 mg of amoxicillin activity and 50 mg of clavulanic acid as the potassium salt. For use in dogs only.

Each 375-mg tablet contains amoxicillin trihydrate equivalent to 300 mg of amoxicillin activity and 75 mg of clavulanic acid as the potassium salt. For use in dogs only.

Dispense according to recommendations outlined in Dosage and Administration section.

SPL UNCLASSIFIED SECTION

Approved by FDA under NADA # 055-099

Clavamox is a trademark owned by and used under license from GlaxoSmithKline.

Augmentin is a trademark owned by GlaxoSmithKline.

Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007

Revised: February 2019

P1518421

PRINCIPAL DISPLAY PANEL - 62.5 mg Tablet Carton

15 strips, 14 tablets each
210 tablets

CLAVAMOX®
(amoxicillin and clavulanate potassium tablets), USP

Veterinary Tablets

For use in dogs and cats

62.5 mg

Approved by FDA under NADA # 055-099

Each film-coated tablet contains amoxicillin trihydrate equivalent to 50 mg of amoxicillin USP activity and 12.5 mg of clavulanic acid USP as the potassium salt..

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian..

zoetis

10000482

PRINCIPAL DISPLAY PANEL - 125 mg Tablet Carton

15 strips, 14 tablets each
210 tablets

CLAVAMOX®
(amoxicillin and clavulanate potassium tablets), USP

Veterinary Tablets

For use in dogs

125 mg

Approved by FDA under NADA # 055-099

Each film-coated tablet contains amoxicillin trihydrate equivalent to 100 mg of amoxicillin USP activity and 25 mg of clavulanic acid USP as the potassium salt.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

zoetis

10000483

PRINCIPAL DISPLAY PANEL - 250 mg Tablet Carton

15 strips, 14 tablets each
210 tablets

CLAVAMOX®
(amoxicillin and clavulanate potassium tablets), USP

Veterinary Tablets

For use in dogs

250 mg

Approved by FDA under NADA # 055-099

Each film-coated tablet contains amoxicillin trihydrate equivalent to 200 mg of amoxicillin USP activity and 50 mg of clavulanic acid USP as the potassium salt.

Caution: Federal law restricts this drug to use by or on the order of a licensed
veterinarian.

zoetis

10000484

 

PRINCIPAL DISPLAY PANEL - 375 mg Tablet Carton

15 strips, 14 tablets each
210 tablets

CLAVAMOX®
(amoxicillin and clavulanate potassium tablets), USP

Veterinary Tablets

For use in dogs

375 mg

Approved by FDA under NADA # 055-099

Each film-coated tablet contains amoxicillin trihydrate equivalent to 300 mg of amoxicillin USP activity and 75 mg of clavulanic acid USP as the potassium salt.

Caution: Federal law restricts this drug to use by or on the order of a licensed
veterinarian.

zoetis

10000486

INGREDIENTS AND APPEARANCE

CLAVAMOX 
amoxicillin and clavulanate potassium tablet, film coated

Product Information
Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC: 54771-8012
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	50 mg
CLAVULANATE POTASSIUM (UNII: Q42OMW3AT8) (CLAVULANIC ACID - UNII:23521W1S24)	CLAVULANIC ACID	12.5 mg

Product Characteristics
Color	WHITE	Score	no score
Shape	ROUND	Size	6mm
Flavor		Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 54771-8012-1	15 in 1 CARTON
1		14 in 1 BLISTER PACK

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA055099	11/09/1984

CLAVAMOX 
amoxicillin and clavulanate potassium tablet, film coated

Product Information
Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC: 54771-8013
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	100 mg
CLAVULANATE POTASSIUM (UNII: Q42OMW3AT8) (CLAVULANIC ACID - UNII:23521W1S24)	CLAVULANIC ACID	25 mg

Product Characteristics
Color	WHITE	Score	no score
Shape	ROUND	Size	9mm
Flavor		Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 54771-8013-1	15 in 1 CARTON
1		14 in 1 BLISTER PACK

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA055099	11/09/1984

CLAVAMOX 
amoxicillin and clavulanate potassium tablet, film coated

Product Information
Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC: 54771-8014
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	200 mg
CLAVULANATE POTASSIUM (UNII: Q42OMW3AT8) (CLAVULANIC ACID - UNII:23521W1S24)	CLAVULANIC ACID	50 mg

Product Characteristics
Color	WHITE	Score	no score
Shape	ROUND	Size	11mm
Flavor		Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 54771-8014-1	15 in 1 CARTON
1		14 in 1 BLISTER PACK

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA055099	11/09/1984

CLAVAMOX 
amoxicillin and clavulanate potassium tablet, film coated

Product Information
Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC: 54771-8018
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	300 mg
CLAVULANATE POTASSIUM (UNII: Q42OMW3AT8) (CLAVULANIC ACID - UNII:23521W1S24)	CLAVULANIC ACID	75 mg

Product Characteristics
Color	WHITE	Score	no score
Shape	ROUND	Size	13mm
Flavor		Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 54771-8018-1	15 in 1 CARTON
1		14 in 1 BLISTER PACK

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA055099	11/09/1984

Labeler - Zoetis Inc. (828851555)